These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 24928790)

  • 1. A novel peptide-based pan-influenza A vaccine: a double blind, randomised clinical trial of immunogenicity and safety.
    Francis JN; Bunce CJ; Horlock C; Watson JM; Warrington SJ; Georges B; Brown CB
    Vaccine; 2015 Jan; 33(2):396-402. PubMed ID: 24928790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the immunogenicity and safety of different doses and formulations of a broad spectrum influenza vaccine (FLU-v) developed by SEEK: study protocol for a single-center, randomized, double-blind and placebo-controlled clinical phase IIb trial.
    van Doorn E; Pleguezuelos O; Liu H; Fernandez A; Bannister R; Stoloff G; Oftung F; Norley S; Huckriede A; Frijlink HW; Hak E
    BMC Infect Dis; 2017 Apr; 17(1):241. PubMed ID: 28376743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell-mediated immune responses to inactivated trivalent influenza-vaccination are decreased in patients with common variable immunodeficiency.
    van Assen S; de Haan A; Holvast A; Horst G; Gorter L; Westra J; Kallenberg CG; Telgt DS; Palache AM; Giezeman KM; Bijl M
    Clin Immunol; 2011 Nov; 141(2):161-8. PubMed ID: 21889412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical testing of pre-pandemic live attenuated A/H5N2 influenza candidate vaccine in adult volunteers: results from a placebo-controlled, randomized double-blind phase I study.
    Rudenko L; Kiseleva I; Stukova M; Erofeeva M; Naykhin A; Donina S; Larionova N; Pisareva M; Krivitskaya V; Flores J;
    Vaccine; 2015 Sep; 33(39):5110-7. PubMed ID: 26296497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity, safety, and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate: a randomised, double-blind, placebo-controlled, phase 2a trial.
    Leroux-Roels I; Willems P; Waerlop G; Janssens Y; Tourneur J; De Boever F; Bruhwyler J; Alhatemi A; Jacobs B; Nicolas F; Leroux-Roels G; Le Vert A
    Lancet Infect Dis; 2023 Dec; 23(12):1360-1369. PubMed ID: 37517422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies of cell-mediated immune responses to influenza vaccination in systemic lupus erythematosus.
    Holvast A; van Assen S; de Haan A; Huckriede A; Benne CA; Westra J; Palache A; Wilschut J; Kallenberg CG; Bijl M
    Arthritis Rheum; 2009 Aug; 60(8):2438-47. PubMed ID: 19644961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
    Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthetic Influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled Phase I trial.
    Pleguezuelos O; Robinson S; Stoloff GA; Caparrós-Wanderley W
    Vaccine; 2012 Jun; 30(31):4655-60. PubMed ID: 22575166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epitope specific T-cell responses against influenza A in a healthy population.
    Savic M; Dembinski JL; Kim Y; Tunheim G; Cox RJ; Oftung F; Peters B; Mjaaland S
    Immunology; 2016 Feb; 147(2):165-77. PubMed ID: 26489873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine.
    Cooper CL; Davis HL; Morris ML; Efler SM; Krieg AM; Li Y; Laframboise C; Al Adhami MJ; Khaliq Y; Seguin I; Cameron DW
    Vaccine; 2004 Aug; 22(23-24):3136-43. PubMed ID: 15297066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-γ T cell responses in humans.
    Peters W; Brandl JR; Lindbloom JD; Martinez CJ; Scallan CD; Trager GR; Tingley DW; Kabongo ML; Tucker SN
    Vaccine; 2013 Mar; 31(13):1752-8. PubMed ID: 23357198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age.
    Vesikari T; Block SL; Guerra F; Lattanzi M; Holmes S; Izu A; Gaitatzis N; Hilbert AK; Groth N
    Pediatr Infect Dis J; 2012 May; 31(5):494-500. PubMed ID: 22301476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of HLA class II H5N1 hemagglutinin epitopes following subvirion influenza A (H5N1) vaccination.
    Zinckgraf JW; Sposato M; Zielinski V; Powell D; Treanor JJ; von Hofe E
    Vaccine; 2009 Aug; 27(39):5393-401. PubMed ID: 19596415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T cell response in healthy adults.
    Pillet S; Aubin É; Trépanier S; Bussière D; Dargis M; Poulin JF; Yassine-Diab B; Ward BJ; Landry N
    Clin Immunol; 2016 Jul; 168():72-87. PubMed ID: 26987887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preferential amplification of CD8 effector-T cells after transcutaneous application of an inactivated influenza vaccine: a randomized phase I trial.
    Combadière B; Vogt A; Mahé B; Costagliola D; Hadam S; Bonduelle O; Sterry W; Staszewski S; Schaefer H; van der Werf S; Katlama C; Autran B; Blume-Peytavi U
    PLoS One; 2010 May; 5(5):e10818. PubMed ID: 20520820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response.
    Taylor DN; Treanor JJ; Sheldon EA; Johnson C; Umlauf S; Song L; Kavita U; Liu G; Tussey L; Ozer K; Hofstaetter T; Shaw A
    Vaccine; 2012 Aug; 30(39):5761-9. PubMed ID: 22796139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Universal H1N1 influenza vaccine development: identification of consensus class II hemagglutinin and neuraminidase epitopes derived from strains circulating between 1980 and 2011.
    Moise L; Terry F; Ardito M; Tassone R; Latimer H; Boyle C; Martin WD; De Groot AS
    Hum Vaccin Immunother; 2013 Jul; 9(7):1598-607. PubMed ID: 23846304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular immune responses of older adults to four influenza vaccines: Results of a randomized, controlled comparison.
    Kumar A; McElhaney JE; Walrond L; Cyr TD; Merani S; Kollmann TR; Halperin SA; Scheifele DW
    Hum Vaccin Immunother; 2017 Sep; 13(9):2048-2057. PubMed ID: 28635557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell responses.
    Kagina BM; Tameris MD; Geldenhuys H; Hatherill M; Abel B; Hussey GD; Scriba TJ; Mahomed H; Sadoff JC; Hanekom WA; ; Mansoor N; Hughes J; de Kock M; Whatney W; Africa H; Krohn C; Veldsman A; Kany AL; Douoguih M; Pau MG; Hendriks J; McClainc B; Benko J; Snowden MA; Hokey DA
    Vaccine; 2014 Oct; 32(45):5908-17. PubMed ID: 25218194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.
    Kreijtz JH; Goeijenbier M; Moesker FM; van den Dries L; Goeijenbier S; De Gruyter HL; Lehmann MH; Mutsert Gd; van de Vijver DA; Volz A; Fouchier RA; van Gorp EC; Rimmelzwaan GF; Sutter G; Osterhaus AD
    Lancet Infect Dis; 2014 Dec; 14(12):1196-207. PubMed ID: 25455987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.